


Supplementary Materials



**Figure S1.** Parental EOL-1 and RS4;11 cells and corresponding sublines overexpressing similar levels of either Siglec-8<sup>FL</sup> and Siglec-8<sup>V-set</sup> were incubated with healthy donor NK cells at an E:T cell ratio of 3:1 with increasing concentrations of the Siglec-8<sup>V-set</sup> antibody, 1H4, in IgG1 format. Non-viable target cells were enumerated after 48 hours via flow cytometry. Mean+SEM values from at least 3 separate experiments are shown. \* $P < 0.05$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .

**Table S1.** Characteristics of patients with eosinophilia from whom primary human eosinophils were derived and used for in vitro experiments.

Patient	Eosinophil count ( $\times 10^9/L$ )	Eosinophil Percentage (%)	White blood cell count ( $\times 10^9/L$ )	Diagnosis
1	13.41	69	19.43	Angioimmunoblastic T-cell lymphoma
2	2.09	28	7.48	Acute myeloid leukemia (trisomy 8)